Taysha Gene Therapies to Host Manufacturing Day

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) announced a virtual manufacturing day for analysts and investors, scheduled for July 27, 2021, from 10:00 a.m. to 1:00 p.m. ET. The event will cover the company’s manufacturing capabilities, regulatory environment, and gene therapy immunology, followed by Q&A sessions. Presentations will feature senior leaders, including Frederick Porter, Greg Gara, and Suyash Prasad. Registration is available via LifeSci Events, and a live video webcast will also be accessible. Taysha is committed to developing AAV-based gene therapies for monogenic CNS diseases.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will host a virtual manufacturing day for analysts and investors. The event will be webcast live on Tuesday, July 27, 2021, from 10:00 a.m. to 1:00 p.m. ET.

Topics of discussion will include the company’s unique three-pillar approach to the manufacturing process, its manufacturing capabilities, the regulatory environment for gene therapy manufacturing, and the immunology of gene therapy. A question and answer session will follow each formal presentation.

The event will feature presentations from Taysha senior leaders:

• Frederick Porter, Ph.D.
  Chief Technical Officer, Taysha Gene Therapies

• Greg Gara
  Senior Vice President, Manufacturing, Taysha Gene Therapies

• Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM
  Chief Medical Officer and Head of Research and Development, Taysha Gene Therapies

Registration for this event is available through LifeSci Events. A live video webcast will be available in the “Events & Media” section of the Taysha corporate website. An archived version of the event will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of our product candidates, including our preclinical product candidates, to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed, the potential market opportunity for these product candidates, our corporate growth plans and our plans to establish a commercial-scale cGMP manufacturing facility to provide preclinical, clinical and commercial supply. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2020, which is available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005181/en/

FAQ

What is the date and time of Taysha's virtual manufacturing day?

Taysha's virtual manufacturing day is scheduled for July 27, 2021, from 10:00 a.m. to 1:00 p.m. ET.

What will be discussed during the manufacturing day for TSHA?

The event will cover Taysha's manufacturing capabilities, regulatory environment, and immunology of gene therapy.

Who will present at the Taysha virtual manufacturing day?

Presentations will be made by Frederick Porter, Greg Gara, and Suyash Prasad.

How can I register for Taysha's virtual manufacturing day?

Registration for the event is available through LifeSci Events.

Will there be a recording of Taysha's virtual manufacturing day?

Yes, an archived version of the event will be available on Taysha's website for 60 days.